Vismodegib - leitarniðurstöður

Bandaríkin - enska - NLM (National Library of Medicine)

erivedge- vismodegib capsule

genentech, inc. - vismodegib (unii: 25x868m3ds) (vismodegib - unii:25x868m3ds) - vismodegib 150 mg - erivedge is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation. none. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to erivedge during pregnancy. report pregnancies to genentech at 1-888-835-2555. risk summary based on its mechanism of action and findings from animal reproduction studies, erivedge can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . in animal reproduction studies, oral administration of vismodegib during organogenesis at doses below the 150 mg clinical dose resulted in embryotoxicity, fetotoxicity, and teratogenicity in rats (see data) . there are no human data on the use of erivedge in pregnant women. advise pregnant women of the potential risk to a fetus. in the u.s. general population, the estim

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

erivedge vismodegib 150 mg hard capsule bottle

roche products pty ltd - vismodegib, quantity: 150 mg - capsule, hard - excipient ingredients: purified talc; iron oxide red; gelatin; sodium starch glycollate; microcrystalline cellulose; titanium dioxide; iron oxide black; shellac; lactose monohydrate; povidone; magnesium stearate; sodium lauryl sulfate - erivedge is indicated for the treatment of adult patients with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma where surgery and/or radiation therapy are not appropriate.

Evrópusambandið - enska - EMA (European Medicines Agency)

erivedge

roche registration gmbh - vismodegib - carcinoma, basal cell - antineoplastic agents - erivedge is indicated for the treatment of adult patients with:- symptomatic metastatic basal cell carcinoma- locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy

Ísrael - enska - Ministry of Health

erivedge

roche pharmaceuticals (israel) ltd - vismodegib - capsules - vismodegib 150 mg - erivedge® is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

erivedge

roche products (nz) ltd - vismodegib 150mg; - capsule - 150 mg - active: vismodegib 150mg excipient: gelatin iron oxide black iron oxide red lactose monohydrate magnesium stearate microcrystalline cellulose opacode black s-1-17822 opacode black s-1-17823 povidone purified talc sodium laurilsulfate sodium starch glycolate titanium dioxide - indicated for the treatment of adult patients with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma where surgery and/or radiation therapy are not appropriate.